Canada · Delayed Price · Currency is CAD VVT Med Statistics
Total Valuation
VVT Med has a market cap or net worth of CAD 15.32 million. The enterprise value is 16.96 million.
| Market Cap | 15.32M |
| Enterprise Value | 16.96M |
Important Dates
The next estimated earnings date is Tuesday, December 1, 2026.
| Earnings Date | Dec 1, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VVT Med has 76.61 million shares outstanding. The number of shares has increased by 229.49% in one year.
| Current Share Class | 76.61M |
| Shares Outstanding | 76.61M |
| Shares Change (YoY) | +229.49% |
| Shares Change (QoQ) | +6.70% |
| Owned by Insiders (%) | 15.85% |
| Owned by Institutions (%) | n/a |
| Float | 64.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 112.39 |
| PB Ratio | -5.90 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 124.43 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.16
| Current Ratio | 0.16 |
| Quick Ratio | 0.03 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.35 |
| Interest Coverage | -14.80 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -446.53% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 192.78% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.23 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -51.81% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -51.81% |
| 50-Day Moving Average | 0.23 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 46.89 |
| Average Volume (20 Days) | 12,516 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, VVT Med had revenue of CAD 136,330 and -5.83 million in losses. Loss per share was -0.07.
| Revenue | 136,330 |
| Gross Profit | -8,521 |
| Operating Income | -4.29M |
| Pretax Income | -5.83M |
| Net Income | -5.83M |
| EBITDA | -4.28M |
| EBIT | -4.29M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 12,781 in cash and 1.65 million in debt, with a net cash position of -1.64 million or -0.02 per share.
| Cash & Cash Equivalents | 12,781 |
| Total Debt | 1.65M |
| Net Cash | -1.64M |
| Net Cash Per Share | -0.02 |
| Equity (Book Value) | -2.60M |
| Book Value Per Share | -0.04 |
| Working Capital | -2.87M |
Cash Flow
In the last 12 months, operating cash flow was -4.66 million and capital expenditures -5,680, giving a free cash flow of -4.67 million.
| Operating Cash Flow | -4.66M |
| Capital Expenditures | -5,680 |
| Depreciation & Amortization | 5,629 |
| Net Borrowing | -236,411 |
| Free Cash Flow | -4.67M |
| FCF Per Share | -0.06 |
Margins
| Gross Margin | -6.25% |
| Operating Margin | -3,144.78% |
| Pretax Margin | -4,279.15% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VVT Med does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -229.49% |
| Shareholder Yield | -229.49% |
| Earnings Yield | -38.07% |
| FCF Yield | -30.47% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 31, 2025. It was a reverse split with a ratio of 0.2141328.
| Last Split Date | Jul 31, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.2141328 |
Scores
VVT Med has an Altman Z-Score of -55.02 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -55.02 |
| Piotroski F-Score | 2 |